There are currently 991 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591
Recruiting
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Register for Updates
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
NCT06860386
Recruiting
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: University of Florida-Genetics- Site Number : 840096, Tampa, Florida
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
NCT04069299
Recruiting
The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radiolabeled somatostatin analog therapy, also referred to as peptide receptor radiotherapy (PRRT), can be a potential alternative in the future. At this time, radiolabeled somatostatin analogs have not been tested in patients with poorly differentiated neuroendocrine carcinomas, and their efficacy in t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: H Lee Moffitt Cancer & Research Institute, Tampa, Florida
Conditions: Neuroendocrine Carcinoma
Register for Updates
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/19/2025
Locations: St. Joseph's Children's Hospital, Tampa, Florida
Conditions: Medulloblastoma
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of South Florida (Tampa General Hospital), Tampa, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922
Recruiting
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Register for Updates
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705
Recruiting
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA rel... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/19/2025
Locations: Clinical Research of West Florida, Tampa, Florida
Conditions: Glenohumeral Osteoarthritis
Register for Updates
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
NCT06315738
Recruiting
The primary objective of this study is to determine the safety and tolerability of two dose levels (0.5 mL/kg and 1.0 mL/kg) of once daily (QD) via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC by incidence of treatment emergent adverse events (TEAEs) and SAEs, with a secondary objective to assess preliminary efficacy of the same two dose levels (0.5 mL/kg and 1.0 mL/kg) of QD via IV route of administration of ST266 in treating patients with... Read More
Gender:
ALL
Ages:
Between 2 weeks and 8 weeks
Trial Updated:
05/19/2025
Locations: BayCare Health System-St. Joseph's Women's Hospital, Tampa, Florida
Conditions: Necrotizing Enterocolitis
Register for Updates
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: GCP Clinical Research, LLC, Tampa, Florida
Conditions: Moderately to Severely Active Crohn Disease
Register for Updates
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
NCT06541262
Recruiting
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/19/2025
Locations: St. Joseph's Children's Hospital, Tampa, Florida
Conditions: Neuroblastoma Recurrent, Ewing's Sarcoma Recurrent, Osteosarcoma Recurrent, Rhabdomyosarcoma Recurrent, Liposarcoma Recurrent
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates